Asensus Surgical Stock Gains On FDA Approval For Articulating Instruments For Its Surgical System

Asensus Surgical Inc ASXC has received FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System technology platform. 

• Articulating instruments offer better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. 
• These instruments have previously received CE Mark for use in the European Union.
• Asensus' Senhance Surgical System is a digital laparoscopic platform that leverages augmented intelligence. 
• Articulating instruments are the latest addition to the Senhance Surgical System, further enhancing surgical performance with robotic precision.
• Price Action: ASXC shares are up 8.56% at $2.35 during the market session on the last check Wednesday.
• Related content: Benzinga's Full FDA Calendar.